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Nicardipine, a new dihydropyridine calcium channel 
blocker, has been investigated for the treatment of coro- 
nary artery disease and heart failure. To assess the inotro- 
pit effect of nicardipine in humans independent of its 
vasodilator effect, equihypotensive doses of intravenous 
nitroprusside (mean infusion rate 65 f 13 &min) and 
nicardipine (mean dose 5.2 + 0.4 mg) were administered to 
15 patients with heart failure (New York Heart Association 
functional classes II to IV, radionuclide left ventricular 
ejection fraction 0.15 f 0.02). Left ventricular microma- 
nometer pressure and simultaneous radionuclide left ven- 
tricular volume were obtained at baseline, during nitro- 
prusside infusion, during a second baseline period and 
during nicardipine infusion. 
Heart rate did not change significantly with either 
nitroprusside or nicardipine. Mean systemic arterial pres- 
sure decreased by an average of 21 mm Hg with both drugs. 
A greater decrease in left ventricular end-diastolic pressure 
occurred with nitroprusside (27 2 2 to 14 f 2 mm Hg, 
p < 0.01) than with nicardipine (27 + 2 to 23 f 3 mm Hg, 
p < 0.05), and pulmonary capillary wedge pressure de- 
Vasodilators have assumed an important role in the short- 
and long-term management of heart failure due to left 
ventricular systolic dysfunction (1,2). As systemic vasodila- 
tors, calcium channel blockers have generated considerable 
interest as agents for the treatment of heart failure (3). 
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creased significantly only with nitroprusside. Cardiac index 
increased from 1.8 f 0.1 to 2.1 + 0.1 literslmin per m* 
(p < 0.05) with nitroprusside and to a greater extent from 
1.7 + 0.1 to 2.4 -I- 0.1 liters/min per m* (p < 0.01) with 
nicardipine. Left ventricular ejection fraction increased 
with nicardipine (0.15 f 0.01 to 0.19 + 0.01, p < O.Ol), but 
not with nitroprusside. 
Peak positive first derivative of left ventricular pressure 
(dP/dt) decreased by 9% with both agents. Left ventricular 
pressure-volume loops were constructed for 14 patients. In 
12 patients, the left ventricular end-systolic pressure- 
volume relation was shifted rightward with nicardipine, 
indicating a negative inotropic effect, with no shift in the 
remaining 2 patients. 
Thus, nicardipine has a negative inotropic effect in 
patients with heart failure. Despite this effect, left ventric- 
ular ejection fraction and cardiac index increased with 
nicardipine. This overall improvement in ventricular sys- 
tolic performance was due to a reduction in afterload. 
(J Am Co11 Cardiol1989;14:1331-8) 
Because calcium channel blockers are coronary as well as 
systemic vasodilators, they may be of particular benefit to 
patients with heart failure due to coronary artery disease, 
especially in patients with manifestations of active ischemia. 
The currently available calcium channel blockers, vera- 
pamil, nifedipine and diltiazem, all have potentially impor- 
tant negative inotropic effects (4-g). Because of these ef- 
fects, efforts are underway to identify newer calcium 
channel blockers with minima1 or absent negative inotropic 
effects. 
Nicardipine is a dihydropyridine calcium channel blocker 
that has been shown to be beneficial in patients with angina 
pectoris (9-13). Administration of nicardipine to patients 
with heart failure has been reported (14-16) to improve 
overall left ventricular systolic performance as a result of 
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afterload reduction. It has been suggested that nicardipine 
has only a minimal negative inotropic effect, which is less 
important than that of nifedipine in vitro (17) in a canine 
mode1 (18) and in patients (19). Clinical assessment of the 
inotropic effect of nicardipine, which is also a potent sys- 
temic vasodilator, has been hindered by the load dependence 
of most indexes of contractility. Recently, the end-systolic 
pressure-volume relation has emerged as a relatively load- 
independent measure of left ventricular contractile function 
(20-26) and has proved useful for the evaluation of new 
drugs for the treatment of heart failure (27). The present 
study utilized the left ventricular end-systolic pressure- 
volume relation to assess the inotropic effect of nicardipine 
in patients with heart failure. 
Methods 
Study patients. The study group comprised 14 men and 1 
woman, aged 63 + 2 years, with chronic heart failure and a 
left ventricular ejection fraction ~0.40. Heart failure was 
due to coronary artery disease in 12 patients and to idio- 
pathic dilated cardiomyopathy in 3. All patients remained 
symptomatic despite treatment with digoxin, diuretic drugs 
and vasodilators. Six patients were in New York Heart 
Association functional class II, four were in class III and five 
were in class IV. All patients had sinus rhythm. The exper- 
imental protocol was approved by the Subcommittee for 
Human Studies of the Massachusetts Genera1 Hospital. 
Informed consent was obtained from all patients. 
Hemodynamic measurements. Patients underwent left 
and right heart catheterization without premeditation 8 to 24 
h after discontinuation of digoxin, diuretic drugs and vasodi- 
lators. Left heart catheterization was performed from the 
femoral approach using a micromanometer catheter (Millar 
Instruments) in 14 patients and a fluid-filled catheter in 1 
patient. Systemic arterial pressure was measured from the 
sidearm of a femoral artery introducer. The following hemo- 
dynamic variables were recorded: heart rate, right atria1 
pressure, pulmonary artery pressure, pulmonary capillary 
wedge pressure, high fidelity left ventricular pressure, mean 
systemic arterial pressure and, by electronic differentiation, 
the first derivative of left ventricular pressure (dP/dt). Left 
ventricular dP/dt was not measured in the one patient 
without micromanometer catheterization. Cardiac index, 
stroke volume, systemic vascular resistance and pulmonary 
vascular resistance were calculated from the cardiac output 
obtained by the thermodilution technique. 
Drug administration. After hemodynamic and radionu- 
elide data were obtained at baseline study, nitroprusside was 
infused at an initial dose of 25 pg/min and titrated upward 
with the goal of achieving a 15 to 20 mm Hg decrease in mean 
systemic arterial pressure. After an equilibration period of 10 
min, hemodynamic data were acquired and radionuclide 
angiography performed. Nitroprusside administration was 
then discontinued, and data were acquired 15 min later when 
mean arterial pressure had returned to its baseline value. 
Nicardipine was then infused at an initial dosage of 1 mglmin 
to achieve a 15 to 20 mm Hg reduction in mean arterial 
pressure (“bolus”) and titrated downward to maintain this 
reduction over a 10 min period (“infusion”), during which 
data were acquired. 
Gated blood pool imaging. Left ventricular volume was 
calculated from supine gated blood pool images, as previ- 
ously described (27,28). Briefly, scans were acquired in the 
anterior (16 frames) and left anterior oblique (32 frames) 
views after labeling of red blood cells in vivo with 30 mCi of 
technetium-99m. With use of the left anterior oblique view, 
a time-activity curve of the left ventricle was constructed by 
a semiautomated edge detection method with a variable 
region of interest. During nitroprusside infusion, the second 
baseline period and nicardipine infusion, images were ac- 
quired in only the left anterior oblique view, and care was 
taken to avoid patient and camera movement during the 
study. Absolute left ventricular end-diastolic volume at 
baseline study was derived from a previously validated 
geometric biplane area-length method (29). Volumes at other 
time points in the cardiac cycle and during the nitroprusside 
infusion, second baseline and nicardipine infusion periods 
were calculated as the baseline end-diastolic volume multi- 
plied by the ratio of counts in a particular frame to counts in 
the baseline end-diastolic frame. Counts were smoothed by 
using a three point weighted moving average (coefficients: 
0.25,0.50, 0.25). Counts in scans obtained during nitroprus- 
side infusion, second baseline and nicardipine infusion peri- 
ods were corrected for differences from the baseline scan in 
acquisition time and frame interval and for physical and 
biologic decay of the isotope. Volumes, and hence pressure- 
volume loops, were obtained in 14 patients. 
Data analysis. High fidelity left ventricular pressure trac- 
ings from four consecutive beats at the midpoint of the gated 
scan acquisition were traced and digitized on a Summa- 
graphics Bitpad interfaced to a VAX 780 computer. Pres- 
sure-volume loops were then constructed by plotting these 
pressures with the corresponding radionuclide ventriculo- 
graphic volumes, starting at a simultaneous time point (the 
peak of the R wave on the electrocardiogram). 
To generate the baseline end-systolic pressure-volume 
relation, nitroprusside, a “pure” vasodilator with no inotro- 
pit effect, was administered to alter end-systolic pressure. 
The baseline end-systolic pressure-volume relation was de- 
termined by the method of Kass et al. (30) from the pressure- 
volume loops (baseline, nitroprusside infusion and second 
baseline periods) obtained for each patient. Points from each 
loop for which the ratio of pressure to volume was maxima1 
were selected, and linear regression analysis of these points 
was performed. The extrapolated volume-axis intercept at 
zero pressure was determined from the regression analysis. 
Points on each loop for which pressure divided by the 
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difference between corresponding volume and the volume- 
axis intercept was maximal were then selected, and a new 
pressure-volume line (with a new volume-axis intercept) was 
generated. This process was iterated until there was no 
change in slope (end-systolic elastance) or volume-axis 
intercept. The coefficients used for weighting the end- 
systolic points derived from the baseline, nitroprusside and 
second baseline pressure-volume loops were 0.25, 0.50 and 
0.25, respectively. 
Stroke work index was determined from the integrated 
area of the pressure-volume loops as stroke work index 
(g-m/m’) = 0.0136 x pressure-volume area (mm Hg- 
ml)/body surface area (m’). 
Statistics. Results are expressed as mean values + SEM. 
Comparisons between two measurements were made by 
paired t test. Comparisons among treatment periods were 
made by analysis of variance, with differences between 
group mean values assessed by the Newman-Keuls test. The 
cumulative binomial distribution test was used to assess the 
significance of the shift of the end-systolic point derived 
during the nicardipine infusion from the baseline end- 
systolic pressure-volume relation. Differences for which the 
p value was co.05 were considered significant. 
Results 
Baseline hemodynamic data (Table 1). Baseline heart rate 
was 87 i 3 beats/min, and mean arterial pressure 94 ? 4 mm 
Hg. Baseline pulmonary capillary wedge (24 * 3 mm Hg) 
and left ventricular end-diastolic (27 2 2 mm Hg) pressures 
were elevated, and cardiac index (1.8 t 0.1 liters/min per 
m2) was depressed. There were no significant differences 
between the two baseline periods in any of the measured or 
derived variables. 
Hemodynamic responses to nitroprusside and nicardipine 
(Table 1, Fig. 1). During nitroprusside infusion (65 2 13 
pg/min), systemic arterial, right atrial, pulmonary artery and 
pulmonary capillary wedge pressures decreased, as did 
systemic and pulmonary vascular resistance. There was no 
significant change in heart rate. Left ventricular end- 
diastolic pressure decreased from 27 of: 2 to 14 + 2 mm Hg 
(p < O.Oi), whereas cardiac index increased from 1.8 -f 0.1 
to 2.1 ? 0.1 liters/min per m2 (p < 0.05). 
Nicardipine administration (bolus dose 1.7 ? 0.2 mg, 
infusion rate 0.27 ? 0.03 mglmin, total dose 5.2 t 0.4 mg) 
caused a decrease in systemic arterial pressure and systemic 
and pulmonary vascular resistance. Heart rate was not 
affected. There was no change in pulmonary artery or 
pulmonary capillary wedge pressures, although left ventric- 
ular end-diastolic pressure decreased slightly (27 f 2 to 23 2 
3 mm Hg, p < 0.05). Cardiac index increased from 1.7 +- 0.1 
to 2.4 t 0.1 liters/min per m2 (p < 0.01). Nicardipine caused 
stroke volume to increase in all patients. Left ventricular 
end-diastolic pressure increased by 3 mm tig in Patient 12 
Table 1. Hemodynamic Response to Nitroprusside and 
Nicardipine in 14 Patients 
Baseline Nitroprusside Baseline Nicardipine 
HR 87 + 3 84 i 3 85 +- 3 84 2 3 
MAP 94 t 4 73 + 2* 91 +4 72 ? 2* 
RAP 621 3 + I* 6r I 7 ? 1: 
PAP 33 ? 3 I9 + 21 33 + 3 31 +- 3t 
PCWP 24 lr 3 II + 2* 24 ? 3 22 +- 3t 
LVEDP 27 ? 2 I4 2 2* 27 + 2 23 t 3*t 
LVESP 94 t 4 74 + 3* 91 -' 4 71 t 3* 
Cl I.8 ? 0.1 2.1 ? 0.1* 1.7 + 0.1 2.4 i O.I*t 
SWI 40 + 6 32 ? 4* 39 + 5 41 t 5 
SVR 2.131 i I50 1,486 + l30* 2,130 k 129 I.170 ? 66*: 
PVR 230 t- 39 167 k 23* 234 k 36 I57 + l8* 
Peak tdP/dt 1.156 i 95 1,030 + 64* 1.070 t 85 959 2 66*t 
LVEDV 412 ? 20 370 I? 21* 409 2 I9 401 ? 2lf 
LVESV 352 t 20 312 ? l9* 347 2 19 328 + 20*t 
LVEF 0.15 2 0.02 0.16 + 0.01 0.15 2 0.01 0.19 ? o.oi*t 
*p i 0.05 drug vs. preceding baseline; tp < 0.05 nicardipine vs. 
nitroprusside. Values shown are mean values + SEM. CI = cardiac index 
(litersimin per m’); HR = heart rate (beatsimin); LVEDP = left ventricular 
end-diastolic pressure (mm Hg); LVEDV = left ventricular end-diastolic 
volume (ml); LVEF = left ventricular ejection fraction: LVESP = left 
ventricular end-systolic pressure (mm Hg); LVESV = left ventricular end- 
systolic volume (ml); MAP = mean systemic arterial pressure (mm Hg); PAP 
= mean pulmonary arterial pressure (mm Hg); PCWP = pulmonary capillary 
wedge pressure (mm Hg); Peak tdP/dt = peak positive left ventricular dP/dt 
(mm Hgis): PVR = pulmonary vascular resistance (dynes-s/cm’); RAP = right 
atrial pressure (mm Hg); SVR = systemic vascular resistance (dynes-s/cm5); 
SW1 = stroke work index (g-m/m*). 
and by 1 mm Hg in Patient 13 and decreased or did not 
change in the other 13 patients. 
Comparison of the effects of nicardipine with those of 
nitroprusside (Fig. 1) shows that for a similar decrease in 
afterload, as measured by mean arterial pressure or left 
ventricular end-systolic pressure, nicardipine caused a larger 
increase in cardiac index (42% compared with 17% with 
nitroprusside, p < 0.01). The greater increase in cardiac 
index during nicardipine administration was attributed to the 
relative maintenance of preload with this drug because left 
ventricular end-diastolic volume decreased from 412 t 20 to 
370 2 21 ml during nitroprusside infusion (p < O.Ol), but 
remained unchanged during the nicardipine infusion (409 t 
19 to 401 i- 21 ml; p = NS). 
Assessment of left ventricular contractile function (Fig. 2). 
Peak positive dP/dt decreased by similar amounts with 
nitroprusside (1,156 2 95 to 1,030 f 64 mm Hg/s, p < 0.01) 
and nicardipine (1,070 f 85 to 959 ? 66 mm Hg/s, p < 0.01). 
Left ventricular ejection fraction was unchanged with nitro- 
prusside, but increased with nicardipine (0.15 ? 0.01 to 0.19 
? 0.01, p < 0.01). Stroke work index, derived from the 
integrated area of the left ventricular pressure-volume loops, 
decreased with nitroprusside (40 -+- 6 to 32 +- 4 g-m/m2, p < 
0.05), but was unchanged with nicardipine. 
Left ventricular pressure-volume loops are shown in 
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Figure 2. The loop obtained during infusion of nicardipine 
was shifted downward and rightward relative to the baseline 
in all but two patients (Cases 6 and 11). This shift in 12 of 14 
patients indicates depression of left ventricular contractile 
function during nicardipine administration compared with 
baseline values (p = 0.012 by the cumulative binomial 
distribution test). 
Side effects. One patient (Case 8) experienced an increase 
in baseline ventricular ectopic activity during nicardipine 
infusion. Sinus bradycardia developed during both nitro- 
prusside and nicardipine infusions in one patient (Case 14), 
and pronounced transitory hypotension occurred with nitro- 
prusside in another (Case 5). No patient suffered from 
hemodynamic decompensation during nicardipine adminis- 
tration, none required specific therapy for side effects and all 
completed the study protocol. 
Discussion 
Many patients with coronary artery disease have mani- 
festations of both active ischemia and heart failure. Others 
have left ventricular systolic dysfunction without symptoms 
and signs of heart failure. Calcium channel blockers may be 
beneficial for both groups of patients because both myocar- 
dial oxygen supply-demand balance and left ventricular 
performance may be improved by the coronary and systemic 
vasodilator effects of these agents. Administration of the 
available calcium channel blockers to patients with systolic 
dysfunction has been limited, however, by theoretical and 
practical concerns related to their negative inotropic effects. 
Effects of available calcium channel blockers on myocardial 
contractility and ventricular performance. The negative ino- 
tropic properties of calcium channel blockers have been 
demonstrated in isolated cardiac muscle preparations 
(31,32). Of the currently available agents-verapamil, dilti- 
azem and nifedipine-verapamil offers the least favorable 
balance between vasodilator and negative inotropic effects 
because of its relatively weak effects as a vasodilator (32). 
Although administration of verapamil to patients with re- 
Figure 1. Relative changes in hemodynamic indexes 
with infusion of nitroprusside (hatched bars) and nicar- 
dipine (solid bars). CI = cardiac index; dP/dt = first 
derivative of left ventricular pressure; HR = heart rate; 
LVEDP = left ventricular end-diastolic pressure; LVEF 
= left ventricular ejection fraction; LVESP = left ven- 
tricular end-systolic pressure; MAP = mean arterial 
pressure; PCWP = pulmonary capillary wedge pres- 
sure; RAP = right arterial pressure; SVR = systemic 
vascular resistance; SW1 = stroke work index. * p < 
0.05 versus preceding baseline; # p < 0.05 versus 
nitroprusside. 
SWI LVEF 
duced left ventricular ejection fraction has been reported 
to improve overall systolic performance in many patients 
(33), it may result in hemodynamic decompensation in oth- 
ers (4). 
Nifedipine, a dihydropyridine derivative, is a more potent 
systemic and coronary vasodilator than is verapamil(32) and 
has generally been reported to bring about an improvement 
in ventricular performance in patients with chronic left 
ventricular dysfunction (34-37). A negative inotropic effect 
of nifedipine, however, has been demonstrated in vivo after 
intracoronary injection in patients with coronary artery 
disease (34,38) and after sublingual administration in patients 
with chronic stable heart failure (6). The clinical importance 
of this negative inotropic effect is underscored by the dem- 
onstration of acute hemodynamic deterioration after admin- 
istration of the drug to some patients (7,8). 
Of the three available agents, diltiazem has undergone 
the least thorough investigation of its inotropic and hemo- 
dynamic effects in patients with heart failure. Although a 
negative inotropic effect has been demonstrated in an animal 
model (5), a study (39) in a small group of patients with heart 
failure did not show such an effect. The negative chronotro- 
pit effect of diltiazem, like that of verapamil, may be 
disadvantageous in patients whose stroke volume is rela- 
tively fixed because of myocardial dysfunction. 
Effects of nicardipine on myoeardial contractility and ven- 
tricular performance. Nicardipine, like nifedipine, is a dihy- 
dropyridine derivative with potent vasodilating and minimal 
negative chronotropic effects. In an in vitro study (17), the 
negative inotropic potency of nicardipine was demonstrated 
to be 10% of that of nifedipine, whereas the vasodilator 
potency of the two drugs was similar. In open chest dogs, the 
cardiodepressant effects of nicardipine were less than those 
of equimolar doses of nifedipine, and the differences were 
accentuated by pretreatment with propranolol (18). Rous- 
seau et al. (19) found that intracoronary administration of 
nicardipine to patients with angina pectoris did not alter left 
ventricular peak positive dP/dt, in contrast to the decrease in 
dP/dt observed after intracoronary administration of nifedi- 
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Figure 2. Pressure-volume loops demonstrating that 
nicardipine infusion was associated with a rightward 
shift from the baseline end-systolic pressure-volume 
relation, indicating a negative inotropic effect, in 12 of 
14 patients (Cases 6 and 11 are exceptions). The line 
connecting the end-systolic points of the first and sec- 
ond baseline and nitroprusside pressure-volume loops, 
the baseline end-systolic pressure-volume relation, was 
derived by an iterative method (see text). 
5 6 
, 80. 100 
pine to patients after coronary artery bypass surgery (34,38). 
In a preliminary report (40), a decrease in dP/dt after 
intracoronary injection of nicardipine was seen in patients 
with coronary artery disease, but this decrease was signifi- 
cantly less (13% versus 34%) than that observed for nifedi- 
pine at equal doses of the two drugs (which produced 
equivalent augmentation of coronary blood flow). 
Thesefindings have spurred investigation of the hemody- 
namic effects of nicardipine in patients with heart failure. 
Several studies (14-16) in such patients have shown that 
cardiac output increases in response to nicardipine. Pulmo- 
nary capillary wedge pressure was observed to decrease by 
a modest amount (14,16) or remain unchanged (15); left 
ventricular end-diastolic pressure was not directly measured 
in these studies. In the present study, we also demonstrated 
o---o lstBasellne 
- Nrtroprusside 
‘z--T3 2”4 Baserlne 
- Nicardipme 
an improvement in left ventricular pump performance, that 
is, an increase in cardiac output with a small decrease in left 
ventricular end-diastolic pressure (although pulmonary cap- 
illary wedge pressure, a less reliable measure of left ventric- 
ular filling pressure, did not decrease significantly). 
Although we observed left ventricular peak positive dP/dt 
to decrease slightly in our patients, this index of contractility 
decreased by a similar amount with nitroprusside, a vasodi- 
later without known inotropic effect. Peak positive dP/dt has 
indeed been demonstrated to be both preload- and afterload- 
dependent (41). Even though left ventricular ejection frac- 
tion did increase, as also observed in a previous study (42), 
this effect was most likely attributable to afterload reduction 
rather than to improvement in inotropic state of the ventri- 
cle. Differentiation of the inotropic effect of nicardipine from 
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its vasodilator effects in these patients required a load- 
independent measure of contractile function. 
Left ventricular end-systolic pressure-volume relation. In 
this study, we utilized the left ventricular end-systolic pres- 
sure-volume relation, a relatively load-insensitive index of 
left ventricular contractile function, to assess whether nicar- 
dipine has a measurable negative inotropic effect in patients 
with heart failure. While it has been recognized for many 
years that the relation between end-systolic pressure and 
volume is independent of end-diastolic volume (43), this 
concept has only recently been applied to the assessment of 
contractility. Suga et al. (20) showed that the end-systolic 
pressure-volume relation in the canine left ventricle is insen- 
sitive to changes in preload, and that the slope of a line 
connecting end-systolic pressure-volume points is sensitive 
to changes in contractility. End-systolic pressure-volume 
analysis was subsequently extended to humans, and was 
shown to be a sensitive indicator of inotropic state indepen- 
dent of loading conditions (22,25,26). We previously demon- 
strated (44) the linearity of the end-systolic pressure-volume 
relation in patients with severe heart failure. 
In the present study, we demonstrated a downward and 
rightward shift of the end-systolic pressure-volume relation 
in the majority (86%) of our patients with heart failure due to 
left ventricular systolic dysfunction. Because of the time 
constraints inherent in a clinical study incorporating left 
heart catheterization, we did not generate pressure-volume 
loops under multiple afterload conditions during nicardipine 
infusion. As a result of this limitation, we could not con- 
struct the full end-systolic pressure-volume relation for the 
left ventricle with nicardipine and, thus, did not determine 
whether the change in the relation was characterized by 
alterations in slope or intercept (that is, a parallel shift), or 
both. Indeed, inotropic interventions have been shown (45) 
to have variable relative effects on the slope and intercept of 
the end-systolic pressure-volume relation. Because end- 
systolic volume was higher with nicardipine than that pre- 
dicted from the baseline end-systolic pressure-volume rela- 
tion for the same end-systolic pressure, we conclude that left 
ventricular contractile performance was depressed by nicar- 
dipine. 
Limitations of the study. Several other limitations of the 
present study must be acknowledged. First, because of time 
constraints, only one nitroprusside dosage and, thus, only 
one diminished afterload condition were utilized to generate 
the baseline end-systolic pressure-volume relation. Con- 
struction of the relation using only two afterload conditions 
is based on the assumption that the relation is linear in this 
range of afterload. Although theoretical considerations (46) 
and experimental data (47,48) indicate nonlinearity of the 
end-systolic pressure-volume relation under certain condi- 
tions, we have shown (44) that the relation is accurately 
represented by a straight line in the “physiologic” range of 
afterload in patients with heart failure. 
Second, it has been suggested that infusion of nitroprus- 
,side alters the end-systolic pressure-volume relation (4950). 
To obviate this limitation by using mechanical rather than 
pharmacologic means to generate the relation would have 
required use of balloon occlusion of the inferior vena cava. 
We have found (51) that such steady state alteration of 
loading conditions can be achieved by inflating a balloon in 
the inferior vena cava below the diaphragm, but that sys- 
temic arterial pressure is not sufficiently reduced by this 
technique to reliably construct the end-systolic pressure- 
volume relation. 
Third, digoxin, diuretic drugs and vasodilators were with- 
drawn only 8 to 24 h before the study. It is possible that 
residual effects of these medications were present. It is 
unlikely, however, that their effects changed between treat- 
ment periods by an amount sufficient to alter our conclu- 
sions. 
Finally, reduction in blood pressure by nitroprusside or 
nicardipine may cause a reflex increase in sympathetic tone, 
associated with a positive inotropic effect. Evidence for 
blunting or absence of this effect in heart failure has been 
demonstrated in a canine model (5) and in humans (6). In the 
present study, we did not measure levels of circulating 
catecholamines, but we observed no increase in heart rate 
associated with the reductions in systemic arterial pressure. 
Summary and implications for therapy. We have shown 
that the acute intravenous administration of nicardipine to 
patients with heart failure is accompanied by measurable 
impairment of left ventricular contractile function. Despite 
this negative inotropic effect, overall left ventricular systolic 
performance is usually enhanced by nicardipine because of 
afterload reduction. Long-term studies enrolling greater 
numbers of patients with oral administration of nicardipine 
will be required to test its clinical efficacy and safety in 
patients with heart failure and myocardial ischemia. In 
patients with heart failure due to causes other than coronary 
artery disease, there is little rationale for prescribing nicar- 
dipine because vasodilators without any negative inotropic 
effect are available. 
We gratefully acknowledge the advice of John B. Newell regarding statistical 
methods. 
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